Genetic markers to distinguish ITP from lupus-related low platelets
Part of Blood & lymphatic, Immune system & allergy, Skin clinical trials.
This study looks at levels of two proteins (interleukin-1β and interleukin-33) in your blood to better understand and tell apart two conditions that cause low platelets. It may help doctors improve diagnosis and treatment for people with these conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 60 years old
- Have a diagnosis of primary ITP (a condition where the immune system destroys platelets) OR SLE (lupus) with low platelet counts
- Have not taken immunosuppressive therapy (medications that suppress the immune system) in the last 4 weeks
- Not have any active infections, cancer, or other autoimmune cytopenias (low blood cell counts caused by the immune system)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at blood test antibodies to help confirm whether low platelet counts are caused by an autoimmune condition. It may help doctors better classify your type of low platelets and guide appropriate next steps.
This trial looks at whether certain proteins in the blood can help doctors diagnose immune thrombocytopenia (ITP), a condition where your immune system destroys platelets. It may help find a faster, simpler way to confirm ITP.
This study tests whether adding another medicine (telitacicept) to a standard platelet-boosting drug (eltrombopag) works better than eltrombopag alone for adults with ITP that hasn't improved with steroids. The goal is to help raise your platelet counts and reduce bleeding risk.
This trial tests sirolimus, an immune-system-calming medicine, for people with lupus who also have very low platelet counts (ITP). It may help reduce bleeding risk and improve platelet numbers.
This study looks at blood and immune system patterns in adults with primary immune thrombocytopenia (ITP) who are starting their first treatment. The goal is to better understand what’s happening in ITP, which may improve how future patients are cared for.
This early-phase trial is testing a new cell therapy for people with certain autoimmune diseases where the immune system attacks blood platelets, causing bleeding problems. The treatment is designed to stop this attack and could be an option if standard medications haven't worked.
Hear when a new Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.